Biotech Values

[DewDiligence]

RGDO terminates PCI-REGULATE study due to safety issues, effectively ending the company’s only clinical-development program:

http://finance.yahoo.com/news/regado-biosciences-permanently-halts-regulate-103000396.html

The DSMB indicated that the level of serious allergic adverse events associated with Revolixys was of a frequency and severity such that they recommended that we do not enroll any further patients in the REGULATE-PCI trial," stated David J. Mazzo, Ph.D., CEO of Regado.

He continued, "We will now undertake a complete review of the unblinded database from REGULATE-PCI, which we expect will take several months to complete."

There’s a CC at 9am ET to talk about this, but there’s not much to say, IMO.

I’ve been bearish on RDGO from day one (#msg-103981014), so today’s news is hardly surprising.